Tamarind Trypsin Inhibitor in Chitosan-Whey Protein Nanoparticles Reduces Fasting Blood Glucose Levels without Compromising Insulinemia: A Preclinical Study
In vivo studies show the benefits of the trypsin inhibitor isolated from tamarind ( L.) (TTI) seeds in satiety and obesity. In the present study, TTI nanoencapsulation (ECW) was performed to potentialize the effect of TTI and allow a controlled release in the stomach. The impact on glycemia, insulin...
Gespeichert in:
| Veröffentlicht in: | Nutrients 2019-11, Vol.11 (11), p.2770 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 11 |
| container_start_page | 2770 |
| container_title | Nutrients |
| container_volume | 11 |
| creator | Matias, Lídia L R Costa, Rafael O A Passos, Thaís S Queiroz, Jaluza L C Serquiz, Alexandre C Maciel, Bruna L L Santos, Pedro P A Camillo, Christina S Gonçalves, Catarina Amado, Isabel R Pastrana, Lorenzo Morais, Ana H A |
| description | In vivo studies show the benefits of the trypsin inhibitor isolated from tamarind (
L.) (TTI) seeds in satiety and obesity. In the present study, TTI nanoencapsulation (ECW) was performed to potentialize the effect of TTI and allow a controlled release in the stomach. The impact on glycemia, insulin, and lipid profile was evaluated in
rats overfed with a high glycemic index diet (HGLI). Characterization of the nanoparticles and in vitro stability in simulated gastrointestinal conditions, monitored by antitrypsin activity and HPLC, was performed. ECW and empty nanoparticles (CW) were administered by gavage, using 12.5 and 10.0 mg/kg, respectively. Both nanoformulations presented a spherical shape and smooth surface, with an average diameter of 117.4 nm (24.1) for ECW and 123.9 nm (11.3) for CW. ECW maintained the antitrypsin activity (95.5%) in the gastric phase, while TTI was completely hydrolyzed. In
rats, the nanoformulations significantly reduced glycemia and HOMA IR, and ECW increased HDL-c compared to CW (
< 0.05).Pancreas histopathology of animals treated with ECW suggested an onset of tissue repair. Thenanoencapsulation provided TTI protection, gradual release in the desired condition, and improvement of biochemical parameters related to carbohydrate metabolism disorders,without compromising insulinemia. |
| doi_str_mv | 10.3390/nu11112770 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6893787</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2315973296</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-9184af9d2e416fa81a9c956946a422e1bab8c5ed9b37e074d3c7234787fdfebb3</originalsourceid><addsrcrecordid>eNqNksFu1DAQhi0EotXSCw-ALHFBSAHHduKYA1JZ0bLSChAs4hg5zqRx5djBdor2XXhYvLSUwom5zIz96dfM6EfocUleMCbJS7eUOagQ5B46pkTQoq45u3-nPkInMV6SQwgiavYQHbFSMFkxeox-7NSkgnE93oX9HI3DGzeaziQfcG7WY66icsXXEfb4Y_AJ8ut75fysQjLaQsSfoF90zmcqJuMu8BvrfY_P7aJ9BLyFK7ARfzdp9EvCaz_NwU8mHsiNi4s1DiajXuHTLA86t0Yriz-npd8_Qg8GZSOc3OQV-nL2drd-V2w_nG_Wp9tCcyZTIcuGq0H2FHhZD6opldSyqiWvFacUyk51ja6glx0TQATvmRaUcdGIoR-g69gKvb7WnZdugl6DS0HZdg4m32bfemXav3-cGdsLf9XWjWRZJgs8uxEI_tsCMbV5Qw3WKgd-iS3lhPCmYv-DsrKSglFZZ_TpP-ilX4LLl_hF8aap8h4r9Pya0sHHGGC4nbsk7cEi7R-LZPjJ3U1v0d-GYD8BsR251w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2315488572</pqid></control><display><type>article</type><title>Tamarind Trypsin Inhibitor in Chitosan-Whey Protein Nanoparticles Reduces Fasting Blood Glucose Levels without Compromising Insulinemia: A Preclinical Study</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Matias, Lídia L R ; Costa, Rafael O A ; Passos, Thaís S ; Queiroz, Jaluza L C ; Serquiz, Alexandre C ; Maciel, Bruna L L ; Santos, Pedro P A ; Camillo, Christina S ; Gonçalves, Catarina ; Amado, Isabel R ; Pastrana, Lorenzo ; Morais, Ana H A</creator><creatorcontrib>Matias, Lídia L R ; Costa, Rafael O A ; Passos, Thaís S ; Queiroz, Jaluza L C ; Serquiz, Alexandre C ; Maciel, Bruna L L ; Santos, Pedro P A ; Camillo, Christina S ; Gonçalves, Catarina ; Amado, Isabel R ; Pastrana, Lorenzo ; Morais, Ana H A</creatorcontrib><description>In vivo studies show the benefits of the trypsin inhibitor isolated from tamarind (
L.) (TTI) seeds in satiety and obesity. In the present study, TTI nanoencapsulation (ECW) was performed to potentialize the effect of TTI and allow a controlled release in the stomach. The impact on glycemia, insulin, and lipid profile was evaluated in
rats overfed with a high glycemic index diet (HGLI). Characterization of the nanoparticles and in vitro stability in simulated gastrointestinal conditions, monitored by antitrypsin activity and HPLC, was performed. ECW and empty nanoparticles (CW) were administered by gavage, using 12.5 and 10.0 mg/kg, respectively. Both nanoformulations presented a spherical shape and smooth surface, with an average diameter of 117.4 nm (24.1) for ECW and 123.9 nm (11.3) for CW. ECW maintained the antitrypsin activity (95.5%) in the gastric phase, while TTI was completely hydrolyzed. In
rats, the nanoformulations significantly reduced glycemia and HOMA IR, and ECW increased HDL-c compared to CW (
< 0.05).Pancreas histopathology of animals treated with ECW suggested an onset of tissue repair. Thenanoencapsulation provided TTI protection, gradual release in the desired condition, and improvement of biochemical parameters related to carbohydrate metabolism disorders,without compromising insulinemia.</description><identifier>ISSN: 2072-6643</identifier><identifier>EISSN: 2072-6643</identifier><identifier>DOI: 10.3390/nu11112770</identifier><identifier>PMID: 31739532</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>animal diseases ; Animals ; Beta cells ; Biological activity ; blood glucose ; Blood Glucose - metabolism ; carbohydrate metabolism ; Chitosan ; Cholesterol, HDL - blood ; Controlled release ; Delayed-Action Preparations ; Diabetes ; Diet ; Efficiency ; Fasting ; Fourier transforms ; Glucose ; Glycemic Index ; Health sciences ; high performance liquid chromatography ; histopathology ; Hydrolysis ; Hyperglycemia - blood ; Hyperglycemia - prevention & control ; hyperinsulinemia ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - pharmacology ; Hypoglycemic Agents - therapeutic use ; in vivo studies ; Insulin ; Insulin - blood ; Insulin Resistance ; laboratory animals ; lipid composition ; Low concentrations ; Male ; Metabolic disorders ; nanocapsules ; Nanoparticles ; Nutrition ; Obesity ; Pancreas ; Pancreas - drug effects ; Pancreas - pathology ; Particle size distribution ; Peptides ; Physiology ; Plant Extracts - administration & dosage ; Plant Extracts - pharmacology ; Plant Extracts - therapeutic use ; Proteins ; rats ; Rats, Wistar ; Rodents ; satiety ; Seeds ; Size distribution ; stomach ; Tamarind ; tamarinds ; Tamarindus - chemistry ; tissue repair ; Trypsin ; Trypsin - metabolism ; Trypsin inhibitors ; Trypsin Inhibitors - administration & dosage ; Trypsin Inhibitors - pharmacology ; Trypsin Inhibitors - therapeutic use ; Whey ; Whey protein ; Whey Proteins</subject><ispartof>Nutrients, 2019-11, Vol.11 (11), p.2770</ispartof><rights>2019. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 by the authors. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-9184af9d2e416fa81a9c956946a422e1bab8c5ed9b37e074d3c7234787fdfebb3</citedby><cites>FETCH-LOGICAL-c439t-9184af9d2e416fa81a9c956946a422e1bab8c5ed9b37e074d3c7234787fdfebb3</cites><orcidid>0000-0002-0724-1961 ; 0000-0002-6460-911X ; 0000-0002-7121-6875 ; 0000-0002-6637-3462 ; 0000-0002-2224-1855</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893787/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893787/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31739532$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matias, Lídia L R</creatorcontrib><creatorcontrib>Costa, Rafael O A</creatorcontrib><creatorcontrib>Passos, Thaís S</creatorcontrib><creatorcontrib>Queiroz, Jaluza L C</creatorcontrib><creatorcontrib>Serquiz, Alexandre C</creatorcontrib><creatorcontrib>Maciel, Bruna L L</creatorcontrib><creatorcontrib>Santos, Pedro P A</creatorcontrib><creatorcontrib>Camillo, Christina S</creatorcontrib><creatorcontrib>Gonçalves, Catarina</creatorcontrib><creatorcontrib>Amado, Isabel R</creatorcontrib><creatorcontrib>Pastrana, Lorenzo</creatorcontrib><creatorcontrib>Morais, Ana H A</creatorcontrib><title>Tamarind Trypsin Inhibitor in Chitosan-Whey Protein Nanoparticles Reduces Fasting Blood Glucose Levels without Compromising Insulinemia: A Preclinical Study</title><title>Nutrients</title><addtitle>Nutrients</addtitle><description>In vivo studies show the benefits of the trypsin inhibitor isolated from tamarind (
L.) (TTI) seeds in satiety and obesity. In the present study, TTI nanoencapsulation (ECW) was performed to potentialize the effect of TTI and allow a controlled release in the stomach. The impact on glycemia, insulin, and lipid profile was evaluated in
rats overfed with a high glycemic index diet (HGLI). Characterization of the nanoparticles and in vitro stability in simulated gastrointestinal conditions, monitored by antitrypsin activity and HPLC, was performed. ECW and empty nanoparticles (CW) were administered by gavage, using 12.5 and 10.0 mg/kg, respectively. Both nanoformulations presented a spherical shape and smooth surface, with an average diameter of 117.4 nm (24.1) for ECW and 123.9 nm (11.3) for CW. ECW maintained the antitrypsin activity (95.5%) in the gastric phase, while TTI was completely hydrolyzed. In
rats, the nanoformulations significantly reduced glycemia and HOMA IR, and ECW increased HDL-c compared to CW (
< 0.05).Pancreas histopathology of animals treated with ECW suggested an onset of tissue repair. Thenanoencapsulation provided TTI protection, gradual release in the desired condition, and improvement of biochemical parameters related to carbohydrate metabolism disorders,without compromising insulinemia.</description><subject>animal diseases</subject><subject>Animals</subject><subject>Beta cells</subject><subject>Biological activity</subject><subject>blood glucose</subject><subject>Blood Glucose - metabolism</subject><subject>carbohydrate metabolism</subject><subject>Chitosan</subject><subject>Cholesterol, HDL - blood</subject><subject>Controlled release</subject><subject>Delayed-Action Preparations</subject><subject>Diabetes</subject><subject>Diet</subject><subject>Efficiency</subject><subject>Fasting</subject><subject>Fourier transforms</subject><subject>Glucose</subject><subject>Glycemic Index</subject><subject>Health sciences</subject><subject>high performance liquid chromatography</subject><subject>histopathology</subject><subject>Hydrolysis</subject><subject>Hyperglycemia - blood</subject><subject>Hyperglycemia - prevention & control</subject><subject>hyperinsulinemia</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>in vivo studies</subject><subject>Insulin</subject><subject>Insulin - blood</subject><subject>Insulin Resistance</subject><subject>laboratory animals</subject><subject>lipid composition</subject><subject>Low concentrations</subject><subject>Male</subject><subject>Metabolic disorders</subject><subject>nanocapsules</subject><subject>Nanoparticles</subject><subject>Nutrition</subject><subject>Obesity</subject><subject>Pancreas</subject><subject>Pancreas - drug effects</subject><subject>Pancreas - pathology</subject><subject>Particle size distribution</subject><subject>Peptides</subject><subject>Physiology</subject><subject>Plant Extracts - administration & dosage</subject><subject>Plant Extracts - pharmacology</subject><subject>Plant Extracts - therapeutic use</subject><subject>Proteins</subject><subject>rats</subject><subject>Rats, Wistar</subject><subject>Rodents</subject><subject>satiety</subject><subject>Seeds</subject><subject>Size distribution</subject><subject>stomach</subject><subject>Tamarind</subject><subject>tamarinds</subject><subject>Tamarindus - chemistry</subject><subject>tissue repair</subject><subject>Trypsin</subject><subject>Trypsin - metabolism</subject><subject>Trypsin inhibitors</subject><subject>Trypsin Inhibitors - administration & dosage</subject><subject>Trypsin Inhibitors - pharmacology</subject><subject>Trypsin Inhibitors - therapeutic use</subject><subject>Whey</subject><subject>Whey protein</subject><subject>Whey Proteins</subject><issn>2072-6643</issn><issn>2072-6643</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNksFu1DAQhi0EotXSCw-ALHFBSAHHduKYA1JZ0bLSChAs4hg5zqRx5djBdor2XXhYvLSUwom5zIz96dfM6EfocUleMCbJS7eUOagQ5B46pkTQoq45u3-nPkInMV6SQwgiavYQHbFSMFkxeox-7NSkgnE93oX9HI3DGzeaziQfcG7WY66icsXXEfb4Y_AJ8ut75fysQjLaQsSfoF90zmcqJuMu8BvrfY_P7aJ9BLyFK7ARfzdp9EvCaz_NwU8mHsiNi4s1DiajXuHTLA86t0Yriz-npd8_Qg8GZSOc3OQV-nL2drd-V2w_nG_Wp9tCcyZTIcuGq0H2FHhZD6opldSyqiWvFacUyk51ja6glx0TQATvmRaUcdGIoR-g69gKvb7WnZdugl6DS0HZdg4m32bfemXav3-cGdsLf9XWjWRZJgs8uxEI_tsCMbV5Qw3WKgd-iS3lhPCmYv-DsrKSglFZZ_TpP-ilX4LLl_hF8aap8h4r9Pya0sHHGGC4nbsk7cEi7R-LZPjJ3U1v0d-GYD8BsR251w</recordid><startdate>20191114</startdate><enddate>20191114</enddate><creator>Matias, Lídia L R</creator><creator>Costa, Rafael O A</creator><creator>Passos, Thaís S</creator><creator>Queiroz, Jaluza L C</creator><creator>Serquiz, Alexandre C</creator><creator>Maciel, Bruna L L</creator><creator>Santos, Pedro P A</creator><creator>Camillo, Christina S</creator><creator>Gonçalves, Catarina</creator><creator>Amado, Isabel R</creator><creator>Pastrana, Lorenzo</creator><creator>Morais, Ana H A</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0724-1961</orcidid><orcidid>https://orcid.org/0000-0002-6460-911X</orcidid><orcidid>https://orcid.org/0000-0002-7121-6875</orcidid><orcidid>https://orcid.org/0000-0002-6637-3462</orcidid><orcidid>https://orcid.org/0000-0002-2224-1855</orcidid></search><sort><creationdate>20191114</creationdate><title>Tamarind Trypsin Inhibitor in Chitosan-Whey Protein Nanoparticles Reduces Fasting Blood Glucose Levels without Compromising Insulinemia: A Preclinical Study</title><author>Matias, Lídia L R ; Costa, Rafael O A ; Passos, Thaís S ; Queiroz, Jaluza L C ; Serquiz, Alexandre C ; Maciel, Bruna L L ; Santos, Pedro P A ; Camillo, Christina S ; Gonçalves, Catarina ; Amado, Isabel R ; Pastrana, Lorenzo ; Morais, Ana H A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-9184af9d2e416fa81a9c956946a422e1bab8c5ed9b37e074d3c7234787fdfebb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>animal diseases</topic><topic>Animals</topic><topic>Beta cells</topic><topic>Biological activity</topic><topic>blood glucose</topic><topic>Blood Glucose - metabolism</topic><topic>carbohydrate metabolism</topic><topic>Chitosan</topic><topic>Cholesterol, HDL - blood</topic><topic>Controlled release</topic><topic>Delayed-Action Preparations</topic><topic>Diabetes</topic><topic>Diet</topic><topic>Efficiency</topic><topic>Fasting</topic><topic>Fourier transforms</topic><topic>Glucose</topic><topic>Glycemic Index</topic><topic>Health sciences</topic><topic>high performance liquid chromatography</topic><topic>histopathology</topic><topic>Hydrolysis</topic><topic>Hyperglycemia - blood</topic><topic>Hyperglycemia - prevention & control</topic><topic>hyperinsulinemia</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>in vivo studies</topic><topic>Insulin</topic><topic>Insulin - blood</topic><topic>Insulin Resistance</topic><topic>laboratory animals</topic><topic>lipid composition</topic><topic>Low concentrations</topic><topic>Male</topic><topic>Metabolic disorders</topic><topic>nanocapsules</topic><topic>Nanoparticles</topic><topic>Nutrition</topic><topic>Obesity</topic><topic>Pancreas</topic><topic>Pancreas - drug effects</topic><topic>Pancreas - pathology</topic><topic>Particle size distribution</topic><topic>Peptides</topic><topic>Physiology</topic><topic>Plant Extracts - administration & dosage</topic><topic>Plant Extracts - pharmacology</topic><topic>Plant Extracts - therapeutic use</topic><topic>Proteins</topic><topic>rats</topic><topic>Rats, Wistar</topic><topic>Rodents</topic><topic>satiety</topic><topic>Seeds</topic><topic>Size distribution</topic><topic>stomach</topic><topic>Tamarind</topic><topic>tamarinds</topic><topic>Tamarindus - chemistry</topic><topic>tissue repair</topic><topic>Trypsin</topic><topic>Trypsin - metabolism</topic><topic>Trypsin inhibitors</topic><topic>Trypsin Inhibitors - administration & dosage</topic><topic>Trypsin Inhibitors - pharmacology</topic><topic>Trypsin Inhibitors - therapeutic use</topic><topic>Whey</topic><topic>Whey protein</topic><topic>Whey Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matias, Lídia L R</creatorcontrib><creatorcontrib>Costa, Rafael O A</creatorcontrib><creatorcontrib>Passos, Thaís S</creatorcontrib><creatorcontrib>Queiroz, Jaluza L C</creatorcontrib><creatorcontrib>Serquiz, Alexandre C</creatorcontrib><creatorcontrib>Maciel, Bruna L L</creatorcontrib><creatorcontrib>Santos, Pedro P A</creatorcontrib><creatorcontrib>Camillo, Christina S</creatorcontrib><creatorcontrib>Gonçalves, Catarina</creatorcontrib><creatorcontrib>Amado, Isabel R</creatorcontrib><creatorcontrib>Pastrana, Lorenzo</creatorcontrib><creatorcontrib>Morais, Ana H A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nutrients</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matias, Lídia L R</au><au>Costa, Rafael O A</au><au>Passos, Thaís S</au><au>Queiroz, Jaluza L C</au><au>Serquiz, Alexandre C</au><au>Maciel, Bruna L L</au><au>Santos, Pedro P A</au><au>Camillo, Christina S</au><au>Gonçalves, Catarina</au><au>Amado, Isabel R</au><au>Pastrana, Lorenzo</au><au>Morais, Ana H A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tamarind Trypsin Inhibitor in Chitosan-Whey Protein Nanoparticles Reduces Fasting Blood Glucose Levels without Compromising Insulinemia: A Preclinical Study</atitle><jtitle>Nutrients</jtitle><addtitle>Nutrients</addtitle><date>2019-11-14</date><risdate>2019</risdate><volume>11</volume><issue>11</issue><spage>2770</spage><pages>2770-</pages><issn>2072-6643</issn><eissn>2072-6643</eissn><abstract>In vivo studies show the benefits of the trypsin inhibitor isolated from tamarind (
L.) (TTI) seeds in satiety and obesity. In the present study, TTI nanoencapsulation (ECW) was performed to potentialize the effect of TTI and allow a controlled release in the stomach. The impact on glycemia, insulin, and lipid profile was evaluated in
rats overfed with a high glycemic index diet (HGLI). Characterization of the nanoparticles and in vitro stability in simulated gastrointestinal conditions, monitored by antitrypsin activity and HPLC, was performed. ECW and empty nanoparticles (CW) were administered by gavage, using 12.5 and 10.0 mg/kg, respectively. Both nanoformulations presented a spherical shape and smooth surface, with an average diameter of 117.4 nm (24.1) for ECW and 123.9 nm (11.3) for CW. ECW maintained the antitrypsin activity (95.5%) in the gastric phase, while TTI was completely hydrolyzed. In
rats, the nanoformulations significantly reduced glycemia and HOMA IR, and ECW increased HDL-c compared to CW (
< 0.05).Pancreas histopathology of animals treated with ECW suggested an onset of tissue repair. Thenanoencapsulation provided TTI protection, gradual release in the desired condition, and improvement of biochemical parameters related to carbohydrate metabolism disorders,without compromising insulinemia.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>31739532</pmid><doi>10.3390/nu11112770</doi><orcidid>https://orcid.org/0000-0002-0724-1961</orcidid><orcidid>https://orcid.org/0000-0002-6460-911X</orcidid><orcidid>https://orcid.org/0000-0002-7121-6875</orcidid><orcidid>https://orcid.org/0000-0002-6637-3462</orcidid><orcidid>https://orcid.org/0000-0002-2224-1855</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6643 |
| ispartof | Nutrients, 2019-11, Vol.11 (11), p.2770 |
| issn | 2072-6643 2072-6643 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6893787 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | animal diseases Animals Beta cells Biological activity blood glucose Blood Glucose - metabolism carbohydrate metabolism Chitosan Cholesterol, HDL - blood Controlled release Delayed-Action Preparations Diabetes Diet Efficiency Fasting Fourier transforms Glucose Glycemic Index Health sciences high performance liquid chromatography histopathology Hydrolysis Hyperglycemia - blood Hyperglycemia - prevention & control hyperinsulinemia Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use in vivo studies Insulin Insulin - blood Insulin Resistance laboratory animals lipid composition Low concentrations Male Metabolic disorders nanocapsules Nanoparticles Nutrition Obesity Pancreas Pancreas - drug effects Pancreas - pathology Particle size distribution Peptides Physiology Plant Extracts - administration & dosage Plant Extracts - pharmacology Plant Extracts - therapeutic use Proteins rats Rats, Wistar Rodents satiety Seeds Size distribution stomach Tamarind tamarinds Tamarindus - chemistry tissue repair Trypsin Trypsin - metabolism Trypsin inhibitors Trypsin Inhibitors - administration & dosage Trypsin Inhibitors - pharmacology Trypsin Inhibitors - therapeutic use Whey Whey protein Whey Proteins |
| title | Tamarind Trypsin Inhibitor in Chitosan-Whey Protein Nanoparticles Reduces Fasting Blood Glucose Levels without Compromising Insulinemia: A Preclinical Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T22%3A19%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tamarind%20Trypsin%20Inhibitor%20in%20Chitosan-Whey%20Protein%20Nanoparticles%20Reduces%20Fasting%20Blood%20Glucose%20Levels%20without%20Compromising%20Insulinemia:%20A%20Preclinical%20Study&rft.jtitle=Nutrients&rft.au=Matias,%20L%C3%ADdia%20L%20R&rft.date=2019-11-14&rft.volume=11&rft.issue=11&rft.spage=2770&rft.pages=2770-&rft.issn=2072-6643&rft.eissn=2072-6643&rft_id=info:doi/10.3390/nu11112770&rft_dat=%3Cproquest_pubme%3E2315973296%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2315488572&rft_id=info:pmid/31739532&rfr_iscdi=true |